Aobiome LLC

Ioannis Gryllos

David R Whitlock

Larry Weiss

Spiros Jamas

This disclosure provides, inter alia, an optimized strain of() designated D23, D23-100, or AOB D23-100.bacteria disclosed in this application have desirable properties, e.g., optimized properties, such as the ability to suppress growth of pathogenic bacteria, and an enhanced ability to produce nitric oxide and nitric oxide precursors. Theherein may be used, for instance, to treat diseases associated with low nitrite levels, skin diseases, and diseases caused by pathogenic bacteria.

Growing community of inventors

Brookline, MA, United States of America

Ioannis Gryllos